Want to join the conversation?
During 2015, $MYL recorded a $97.4MM net gain for litigation settlements vs. a net charge of $47.9MM in the prior year. The gain in 2015 was primarily related to the settlement of the Paroxetine CR matter with $GSK for approx. $113MM and the settlement of certain antitrust matters, partially offset by the settlement of patent infringement matters.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)